Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.

	Dec '20	Dec '21
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	314.01K -	714.79K 127.64%
selling general and administrative expenses	314.01K -	714.79K 127.64%
research and development expenses	1.35M -	188.62K 86.05%
other expenses
cost and expenses	1.67M -	903.41K 45.79%
operating expenses	1.67M -	903.41K 45.79%
interest expense	34.39K -	53.55K 55.71%
ebitda	-1.67M -	-903.41K 45.79%
operating income	-1.67M -	-903.41K 45.79%
depreciation and amortization
total other income expenses net	-34.39K -	-53.55K 55.71%
income before tax	-1.70M -	-956.95K 43.73%
income tax expense	34.39K -	53.55K 55.71%
net income	-1.74M -	-1.01M 41.76%
weighted average shs out	12.53M -	9.69M 22.68%
weighted average shs out dil	12.53M -	9.69M 22.68%
eps	-0.14 -	-0.10 28.57%
epsdiluted	-0.14 -	-0.10 28.57%

ALPX

NASDAQ:ALPX

Alopexx, Inc.

PE Ratio

0.00

PFCF: -

Preview